Cargando…
A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products
Nicotine replacement therapies (NRTs) are intended for short-term use to help cigarette smokers to quit. Some smokers find NRTs ineffective or seek a more satisfactory source of nicotine. Tobacco-free oral nicotine pouch (NP) products have emerged as a potential reduced risk product compared with ci...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050656/ https://www.ncbi.nlm.nih.gov/pubmed/35484309 http://dx.doi.org/10.1038/s41598-022-10544-x |
_version_ | 1784696416368590848 |
---|---|
author | Azzopardi, David Ebajemito, James McEwan, Michael Camacho, Oscar M. Thissen, Jesse Hardie, George Voisine, Richard Mullard, Gavin Cohen, Zvi Murphy, James |
author_facet | Azzopardi, David Ebajemito, James McEwan, Michael Camacho, Oscar M. Thissen, Jesse Hardie, George Voisine, Richard Mullard, Gavin Cohen, Zvi Murphy, James |
author_sort | Azzopardi, David |
collection | PubMed |
description | Nicotine replacement therapies (NRTs) are intended for short-term use to help cigarette smokers to quit. Some smokers find NRTs ineffective or seek a more satisfactory source of nicotine. Tobacco-free oral nicotine pouch (NP) products have emerged as a potential reduced risk product compared with cigarettes and other tobacco products. In a randomised crossover clinical study, thirty-four healthy adult smokers were enrolled and their nicotine C(max) and AUC(0-T) determined for three 4 mg nicotine products (NP, gum, lozenge) under fasting conditions. The NP, lozenge and gum mean C(max) values were 8.5, 8.3 and 4.4 ng/mL, AUC(0-T) values were 30.6, 31.5 and 14.3 ng*h/mL, respectively. The NP showed similar nicotine bioavailability to the lozenge (p = 0.6526 (C(max)), p = 1.0000 (AUC(0-T))), and superior bioavailability to the gum (p < 0.0001 for C(max) and AUC(0-T)). Compared with the lozenge, the NP demonstrated greater product satisfaction with a higher number of positive responses to subjective satisfaction questions. All products were judged to be well-tolerated; the incidence of minor adverse events was lower for the NP (18.2%) than the lozenge (33.3%) or gum (18.8%). In summary, NPs may provide smokers with a more satisfying alternative nicotine source as compared to the reference NRTs. Study Registry/Registered Trial No: ISRCTN/ISRCTN65708311. |
format | Online Article Text |
id | pubmed-9050656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90506562022-04-30 A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products Azzopardi, David Ebajemito, James McEwan, Michael Camacho, Oscar M. Thissen, Jesse Hardie, George Voisine, Richard Mullard, Gavin Cohen, Zvi Murphy, James Sci Rep Article Nicotine replacement therapies (NRTs) are intended for short-term use to help cigarette smokers to quit. Some smokers find NRTs ineffective or seek a more satisfactory source of nicotine. Tobacco-free oral nicotine pouch (NP) products have emerged as a potential reduced risk product compared with cigarettes and other tobacco products. In a randomised crossover clinical study, thirty-four healthy adult smokers were enrolled and their nicotine C(max) and AUC(0-T) determined for three 4 mg nicotine products (NP, gum, lozenge) under fasting conditions. The NP, lozenge and gum mean C(max) values were 8.5, 8.3 and 4.4 ng/mL, AUC(0-T) values were 30.6, 31.5 and 14.3 ng*h/mL, respectively. The NP showed similar nicotine bioavailability to the lozenge (p = 0.6526 (C(max)), p = 1.0000 (AUC(0-T))), and superior bioavailability to the gum (p < 0.0001 for C(max) and AUC(0-T)). Compared with the lozenge, the NP demonstrated greater product satisfaction with a higher number of positive responses to subjective satisfaction questions. All products were judged to be well-tolerated; the incidence of minor adverse events was lower for the NP (18.2%) than the lozenge (33.3%) or gum (18.8%). In summary, NPs may provide smokers with a more satisfying alternative nicotine source as compared to the reference NRTs. Study Registry/Registered Trial No: ISRCTN/ISRCTN65708311. Nature Publishing Group UK 2022-04-28 /pmc/articles/PMC9050656/ /pubmed/35484309 http://dx.doi.org/10.1038/s41598-022-10544-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Azzopardi, David Ebajemito, James McEwan, Michael Camacho, Oscar M. Thissen, Jesse Hardie, George Voisine, Richard Mullard, Gavin Cohen, Zvi Murphy, James A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
title | A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
title_full | A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
title_fullStr | A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
title_full_unstemmed | A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
title_short | A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
title_sort | randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050656/ https://www.ncbi.nlm.nih.gov/pubmed/35484309 http://dx.doi.org/10.1038/s41598-022-10544-x |
work_keys_str_mv | AT azzopardidavid arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT ebajemitojames arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT mcewanmichael arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT camachooscarm arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT thissenjesse arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT hardiegeorge arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT voisinerichard arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT mullardgavin arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT cohenzvi arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT murphyjames arandomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT azzopardidavid randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT ebajemitojames randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT mcewanmichael randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT camachooscarm randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT thissenjesse randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT hardiegeorge randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT voisinerichard randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT mullardgavin randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT cohenzvi randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts AT murphyjames randomisedstudytoassessthenicotinepharmacokineticsofanoralnicotinepouchandtwonicotinereplacementtherapyproducts |